Clinical Cancer Research · 2015 · 227 citations · 27 references
MedicineOncologyPharmacologyChemotherapyMetastasisNeuro-oncologyBrain MetastasesBrain MetastasisBrain TumorsMetastatic Brain TumorsMetastatic Disease TreatmentNeuro-oncology Clinical TrialsBrain Metastasis Systemic TherapyBrain Metastasis TrialsHemorrhagic Brain MetastasesIntracranial Hemorrhage PharmacotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPhase Ii InvestigationSymptomatic Intracranial Hemorrhage
PURPOSE: The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated patients with non-small cell lung cancer (NSCLC) and asymptomatic untreated brain metastases to provide data in this previously unexplored subgroup. EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve ×6) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). Six-month progression-free survival (PFS) was the primary endpoint. The trial could be stopped if there were more than three (B + CP) or more than two (B + E) intracranial hemorrhages. RESULTS: In first-line B + CP cohort (n = 67), 6-month PFS rate was 56.5% with a median PFS of 6.7 months [95% confidence interval (CI), 5.7-7.1] and median overall survival (OS) of 16.0 months. Investigator-assessed overall response rate (ORR) was 62.7%: 61.2% in intracranial lesions and 64.2% in extracranial lesions. Because of low enrolment (n = 24), efficacy results for the second-line B + E cohort were exploratory only; 6-month PFS rate was 57.2%, median PFS was 6.3 months (95% CI, 3.0-8.4), median OS was 12.0 months, and ORR was 12.5%. Adverse events were comparable with previous trials of bevacizumab. One grade 1 intracranial hemorrhage occurred and resolved without sequelae. CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases.
27
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Laurie E. Gaspar, Charles Scott, Marvin Rotman et al. · International Journal of Radiation Oncology*Biology*Physics · 1997 · 2.6K citations · Full text
David W. Andrews, Charles Scott, Paul W. Sperduto et al. · The Lancet · 2004 · 2.4K citations
Epidemiology of Brain Metastases
Lakshmi Nayak, Eudocia Q. Lee, Patrick Y. Wen · Current Oncology Reports · 2011 · 1.4K citations
Paul W. Sperduto, Brian Berkey, Laurie E. Gaspar et al. · International Journal of Radiation Oncology*Biology*Physics · 2007 · 1K citations
Medicine, Oncology, Metastasis +11